Addex Therapeutics Ltd American Depositary Shares
ADXNStock
$5.94−29.05%52W
Market Cap$5.84M
P/E0.80x
Div yield—
Beta-0.03
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-33.65%
Price vs S&P 500 (4W)-9.29%
VGM Score27.51
Market Capitalization$5.84M
P/E Ratio (Annual)0.80x
Analyst Recommendations
Oct 2025
Nov 2025
Dec 2025
Jan 2026
2.00
2.00
2.00
2.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ADXNAddex Therapeutics Ltd American Depositary Shares | D | F | D | $5.94 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company specializing in the development of allosteric modulators, an emerging class of orally available small-molecule drugs. Operating from its base in Switzerland and Europe, the company focuses on the discovery, development, and commercialization of these novel therapeutics.